Edition:
United Kingdom

Astrazeneca Says Selumetinib Gets Breakthrough Therapy Designation


Monday, 1 Apr 2019 

April 1 (Reuters) - AstraZeneca PLC ::SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION.BREAKTHROUGH THERAPY DESIGNATION BASED ON PHASE II SPRINT TRIAL IN PAEDIATRIC PATIENTS WITH NF1 PLEXIFORM NEUROFIBROMAS.SELUMETINIB IS A MEK 1/2 INHIBITOR BEING CO-DEVELOPED BY ASTRAZENECA AND MERCK & CO .